263 related articles for article (PubMed ID: 37464963)
1. Real-world evidence of outcomes of oligometastatic hormone-sensitive prostate cancer patients treated with metastasis-directed therapy.
Wenzel M; Garcia CC; Hoeh B; Jorias C; Humke C; Koll F; Tselis N; Rödel C; Graefen M; Tilki D; Chun FKH; Mandel P
Prostate; 2023 Oct; 83(14):1365-1372. PubMed ID: 37464963
[TBL] [Abstract][Full Text] [Related]
2. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
Battaglia A; De Meerleer G; Tosco L; Moris L; Van den Broeck T; Devos G; Everaerts W; Joniau S
Eur Urol Oncol; 2019 Mar; 2(2):174-188. PubMed ID: 31017094
[TBL] [Abstract][Full Text] [Related]
3. Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial.
Privé BM; Janssen MJR; van Oort IM; Muselaers CHJ; Jonker MA; de Groot M; Mehra N; Verzijlbergen JF; Scheenen TWJ; Zámecnik P; Barentsz JO; Gotthardt M; Noordzij W; Vogel WV; Bergman AM; van der Poel HG; Vis AN; Oprea-Lager DE; Gerritsen WR; Witjes JA; Nagarajah J
BMC Cancer; 2020 Sep; 20(1):884. PubMed ID: 32928177
[TBL] [Abstract][Full Text] [Related]
4. Natural course of metastatic castration-resistant prostate cancer in the era of intensified androgen deprivation therapy in the hormone-sensitive setting.
Gebrael G; Hage Chehade C; Sayegh N; Tripathi N; Chigarira B; Goel D; Nordblad B; McFarland TR; Narang A; Srivastava A; Tandar C; Dal E; Jo Y; Galarza Fortuna G; Mathew Thomas V; Sahu KK; Li H; Maughan BL; Swami U; Agarwal N
Prostate; 2024 Jun; 84(9):888-892. PubMed ID: 38561317
[TBL] [Abstract][Full Text] [Related]
5. Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis.
Wenzel M; Würnschimmel C; Nocera L; Collà Ruvolo C; Tian Z; Shariat SF; Saad F; Briganti A; Tilki D; Graefen M; Kluth LA; Roos FC; Mandel P; Chun FKH; Karakiewicz PI
Eur Urol Focus; 2022 Mar; 8(2):399-408. PubMed ID: 33853754
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy.
Yanagisawa T; Hata K; Narita S; Hatakeyama S; Mori K; Yata Y; Sano T; Otsuka T; Hara S; Miyajima K; Enei Y; Fukuokaya W; Nakazono M; Matsukawa A; Miki J; Habuchi T; Ohyama C; Shariat SF; Kimura T
Prostate; 2023 May; 83(6):563-571. PubMed ID: 36661102
[TBL] [Abstract][Full Text] [Related]
7. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
8. Oncological and perioperative outcomes of surgery with or without metastasis-directed therapy as part of a multimodal treatment in men with de-novo oligometastatic prostate cancer.
Pellegrino A; Gandaglia G; de Angelis M; Fallara G; Mazzone E; Stabile A; Pellegrino F; Robesti D; Leni R; Scuderi S; Cucchiara V; Cirulli GO; Barletta F; Montorsi F; Briganti A
World J Urol; 2023 Aug; 41(8):2069-2076. PubMed ID: 37326656
[TBL] [Abstract][Full Text] [Related]
9. Oligorecurrent prostate cancer treated with metastases-directed therapy or standard of care: a single-center experience.
Boeri L; Sharma V; Kwon E; Stish BJ; Davis BJ; Karnes RJ
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):514-523. PubMed ID: 33268854
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer.
Rogowski P; Trapp C; von Bestenbostel R; Schmidt-Hegemann NS; Shi R; Ilhan H; Kretschmer A; Stief C; Ganswindt U; Belka C; Li M
Radiat Oncol; 2021 Jun; 16(1):125. PubMed ID: 34193194
[TBL] [Abstract][Full Text] [Related]
11. Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial.
Ost P; Reynders D; Decaestecker K; Fonteyne V; Lumen N; De Bruycker A; Lambert B; Delrue L; Bultijnck R; Claeys T; Goetghebeur E; Villeirs G; De Man K; Ameye F; Billiet I; Joniau S; Vanhaverbeke F; De Meerleer G
J Clin Oncol; 2018 Feb; 36(5):446-453. PubMed ID: 29240541
[TBL] [Abstract][Full Text] [Related]
12. Toxicity and Efficacy of Concurrent Androgen Deprivation Therapy, Pelvic Radiotherapy, and Radium-223 in Patients with
Turner PG; Jain S; Cole A; Grey A; Mitchell D; Prise KM; Hounsell AR; McGarry CK; Biggart S; O'Sullivan JM
Clin Cancer Res; 2021 Aug; 27(16):4549-4556. PubMed ID: 34187853
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of Adding Docetaxel to Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer in Korean Real-World Practice.
Park K; Kim JY; Park I; Shin SH; Lee HJ; Lee JL
Yonsei Med J; 2023 Feb; 64(2):86-93. PubMed ID: 36719015
[TBL] [Abstract][Full Text] [Related]
14. [Treatment concepts for primary oligometastatic prostate cancer].
Knipper S; Graefen M; Hadaschik B; Wiegel T
Urologe A; 2020 Jun; 59(6):659-664. PubMed ID: 32274541
[TBL] [Abstract][Full Text] [Related]
15. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
16. SPARKLE: a new spark in treating oligorecurrent prostate cancer: adding systemic treatment to stereotactic body radiotherapy or metastasectomy: key to long-lasting event-free survival?
Rans K; Charlien B; Filip A; Olivier H; Julie DH; Céderic D; Herlinde D; Benedikt E; Karolien G; Annouschka L; Nick L; Kenneth P; Carl S; Koen S; Hans V; Ben V; Steven J; Gert M
BMC Cancer; 2022 Dec; 22(1):1294. PubMed ID: 36503429
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Novel Hormone Agents in the Treatment of Metastatic Castration-resistant Prostate Cancer: A Real-world Retrospective Study.
Li JR; Wang SS; Chen CS; Yang CK; Lu K; Cheng CL; Hung SC; Chen SY; Hsu CY; Chiu KY
Anticancer Res; 2022 Oct; 42(10):4857-4866. PubMed ID: 36191989
[TBL] [Abstract][Full Text] [Related]
18. Treatment outcomes for patients with metastatic castrate-resistant prostate cancer following docetaxel for hormone-sensitive disease.
Schmidt A; Anton A; Shapiro J; Wong S; Azad A; Kwan E; Spain L; Muthusamy A; Torres J; Parente P; Parnis F; Goh J; Joshua AM; Pook D; Gibbs P; Tran B; Weickhardt A
Asia Pac J Clin Oncol; 2021 Feb; 17(1):36-42. PubMed ID: 32970925
[TBL] [Abstract][Full Text] [Related]
19. Impact of next-generation hormonal agents on treatment patterns among patients with metastatic hormone-sensitive prostate cancer: a real-world study from the United States, five European countries and Japan.
Leith A; Ribbands A; Kim J; Clayton E; Gillespie-Akar L; Yang L; Ghate SR
BMC Urol; 2022 Mar; 22(1):33. PubMed ID: 35277153
[TBL] [Abstract][Full Text] [Related]
20. The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES.
Armstrong AJ; Iguchi T; Azad AA; Villers A; Alekseev B; Petrylak DP; Szmulewitz RZ; Alcaraz A; Shore ND; Holzbeierlein J; Gomez-Veiga F; Rosbrook B; Zohren F; Haas GP; Gourgiotti G; El-Chaar N; Stenzl A
Eur Urol; 2023 Aug; 84(2):229-241. PubMed ID: 37179240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
